News

OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Pontifax Ventures

Oxurion NV a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular retinal disorders, announces it has entered into a EUR 10 million loan agreement with Kreos Capital and Pontifax Ventures, which will take the form of convertible bonds (the “Debt Financing”).

Oxurion is focused on building a leading global franchise in the treatment of retinal vascular disorders based on the successful development of its two novel therapeutics. The net proceeds of the Debt Financing will be used to provide working capital to support Oxurion’s strategy to progress the development of its two clinical stage assets, THR-687 and THR-149 currently in Phase 2 clinical trials for diabetic macular edema (“DME”) (the “Clinical Assets”).

 

Full Article here: https://www.globenewswire.com/news-release/2021/11/22/2338605/0/en/OXURION-NV-Secures-EUR-10-Million-Convertible-Bond-Financing-from-Kreos-Capital-and-Pontifax-Ventures.html